1. Vargesson N (2015) Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 105(2):140–156.
https://doi.org/10.1002/bdrc.21096
2. Physicians’ desk reference 71st ed. (2017). PDR network, Montvale, New Jersey, USA
3. European Medicines Agency, CHMP (2008) Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling, EMEA/CHMP/203927/2005, publication date 24/07/2008.
http://www.ema.europa.eu
4. Food and Drug Administration, content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling, publication date 09/10/2014.
http://federalregister.gov/a/2014-28241
5. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12(3):244–252.
https://doi.org/10.1016/S1474–4422(1012)70323-X